Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6-17 months of age: dosing studies in different age groups.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Vaccine

• Publication date

  2006-03-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.VACCINE.2005.08.110PMID 16257098
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Progress in enteric vaccine development

  2004cited by this paper
• Microbial-gut interactions in health and disease. Progress in enteric vaccine development.

  2004cited by this paper
• Influenza in children.

  2003cited by this paper
• Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18-36 months of age.

  2003cited by this paper
• Combined hepatitis A and B vaccines: a review of their immunogenicity and tolerability.

  2003cited by this paper
• Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants

  2002cited by this paper
• Dose-Dependent Circulating Immunoglobulin A Antibody-Secreting Cell and Serum Antibody Responses in Swedish Volunteers to an Oral Inactivated Enterotoxigenic Escherichia coli Vaccine

  2001cited by this paper
• Induction of Systemic Antifimbria and Antitoxin Antibody Responses in Egyptian Children and Adults by an Oral, Killed Enterotoxigenic Escherichia coli plus Cholera Toxin B Subunit Vaccine

  2001cited by this paper
• Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi adults and children.

  2000cited by this paper
• Prevalence of Toxin Types and Colonization Factors in Enterotoxigenic Escherichia coli Isolated during a 2-Year Period from Diarrheal Patients in Bangladesh

  2000cited by this paper
• Oral, inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine: results of the initial evaluation in children. PRIDE Study Group.

  1999cited by this paper
• Safety and immunogenicity of an oral, killed enterotoxigenic Escherichia coli-cholera toxin B subunit vaccine in Egyptian adults.

  1998cited by this paper
• Safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli vaccine.

  1998cited by this paper
• Drug Use in Assisted Suicide and Euthanasia

  1997cited by this paper
• Intestinal antibody response after oral immunization with a prototype cholera B subunit-colonization factor antigen enterotoxigenic Escherichia coli vaccine.

  1993cited by this paper
• Antibody-secreting cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine

  1992cited by this paper
• New Generation Vaccines

  1990cited by this paper
• Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development.

  1989cited by this paper
• A novel two colour ELISPOT assay. I. Simultaneous detection of distinct types of antibody-secreting cells.

  1988cited by this paper
• Serologic differentiation between antitoxin responses to infection with Vibrio cholerae and enterotoxin-producing Escherichia coli.

  1983cited by this paper
• Incidence and severity of rotavirus and Escherichia coli diarrhoea in rural Bangladesh. Implications for vaccine development.

  1981cited by this paper

• Vaccine Candidates Designed to Prevent Enterotoxigenic Escherichia coli Diarrhoea: A Scoping Review of Clinical Trials Evaluating Vaccine Candidates in Development

  2026cites this paper
• Recent progress in enterotoxigenic Escherichia coli vaccine research and development

  2025cites this paper
• Single domain antibodies from camelids in the treatment of microbial infections

  2024cites this paper
• Age-dependent pathogenic profiles of enterotoxigenic Escherichia coli diarrhea in Bangladesh

  2024cites this paper
• Developments in oral enterotoxigenic Escherichia coli vaccines.

  2023cites this paper
• Oral inactivated whole cell vaccine for mucosal immunization: ETVAX case study

  2023cites this paper
• Antibody response to 1.0 and 0.5 mL doses of an inactivated bacterial vaccine against bovine respiratory disease in young Holstein calves: a field trial

  2023cites this paper
• Intradermally Administered Enterotoxigenic Escherichia coli Vaccine Candidate MecVax Induces Functional Serum Immunoglobulin G Antibodies against Seven Adhesins (CFA/I and CS1 through CS6) and Both Toxins (STa and LT)

  2021cites this paper
• Formaldehyde effects on kanamycin resistance gene of inactivated recombinant Escherichia coli vaccines

  2020cites this paper
• Oral Vaccines for Enterotoxigenic Escherichia coli

  2020cites this paper
• Development of effective vaccines for enterotoxigenic Escherichia coli.

  2019cites this paper
• Live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine with dmLT adjuvant protects human volunteers against virulent experimental ETEC challenge

  2019cites this paper
• Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses

  2019cites this paper
• Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial

  2019cites this paper
• The oral cholera vaccine Shanchol™ when stored at elevated temperatures maintains the safety and immunogenicity profile in Bangladeshi participants.

  2016cites this paper
• Induction of long term mucosal immunological memory in humans by an oral inactivated multivalent enterotoxigenic Escherichia coli vaccine.

  2016cites this paper
• Genetic Fusions of a CFA/I/II/IV MEFA (Multiepitope Fusion Antigen) and a Toxoid Fusion of Heat-Stable Toxin (STa) and Heat-Labile Toxin (LT) of Enterotoxigenic Escherichia coli (ETEC) Retain Broad Anti-CFA and Antitoxin Antigenicity

  2015cites this paper
• Current Progress in Developing Subunit Vaccines against Enterotoxigenic Escherichia coli-Associated Diarrhea

  2015cites this paper
• Approaches to Enhance and Evaluate the Immunogenicity of an Oral ETEC Vaccine

  2015cites this paper
• Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study.

  2014cites this paper
• Multiepitope Fusion Antigen Induces Broadly Protective Antibodies That Prevent Adherence of Escherichia coli Strains Expressing Colonization Factor Antigen I (CFA/I), CFA/II, and CFA/IV

  2013cites this paper
• Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea.

  2013cites this paper
• Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA/I overexpressing bacteria and recombinantly produced LTB/CTB hybrid protein.

  2013cites this paper
• Strategies to overexpress enterotoxigenic Escherichia coli (ETEC) colonization factors for the construction of oral whole-cell inactivated ETEC vaccine candidates

  2012cites this paper
• Recent progress toward an enterotoxigenic Escherichia coli vaccine

  2012cites this paper
• The Oral, Live Attenuated Enterotoxigenic Escherichia coli Vaccine ACE527 Reduces the Incidence and Severity of Diarrhea in a Human Challenge Model of Diarrheal Disease

  2012cites this paper
• Progress and hurdles in the development of vaccines against enterotoxigenic Escherichia coli in humans

  2012cites this paper
• From cholera to enterotoxigenic Escherichia coli (ETEC) vaccine development

  2011cites this paper
• Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.

  2011cites this paper
• Oral vaccines for preventing cholera.

  2011cites this paper
• Construction of a non-toxigenic Escherichia coli oral vaccine strain expressing large amounts of CS6 and inducing strong intestinal and serum anti-CS6 antibody responses in mice.

  2011cites this paper
• Mucosal immunization: A realistic alternative

  2010cites this paper
• Construction and expression of immunogenic hybrid enterotoxigenic Escherichia coli CFA/I and CS2 colonization fimbriae for use in vaccines

  2010influential citation
• Zinc influences innate immune responses in children with enterotoxigenic Escherichia coli-induced diarrhea.

  2010cites this paper
• The ABC of clinical and experimental adjuvants--a brief overview.

  2010cites this paper
• Over-expression of major colonization factors of enterotoxigenic Escherichia coli, alone or together, on non-toxigenic E. coli bacteria.

  2010cites this paper
• Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine

  2010cites this paper
• Characterization of the most prevalent colonization factor antigens present in Chilean clinical enterotoxigenic Escherichia coli strains using a new multiplex polymerase chain reaction.

  2009cites this paper
• CD4+ T-cell responses to an oral inactivated cholera vaccine in young children in a cholera endemic country and the enhancing effect of zinc supplementation.

  2009cites this paper
• Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding.

  2009cites this paper
• Vaccination against cholera and ETEC diarrhea and interventions to improve vaccine immune responses.

  2009cites this paper
• Gastrointestinal infectionsBacterial gastroenteritis

  2009cites this paper
• Determinanten für Reaktionen auf orale Impfstoffe in Entwicklungsländern

  2009cites this paper
• Determinantes de las respuestas a vacunas orales en países en vías de desarrollo

  2009cites this paper
• Infectious Diseases and Vaccine Sciences: Strategic Directions

  2008cites this paper
• Déterminants des réponses aux vaccins oraux dans les pays en développement

  2008cites this paper
• Determinants of Responses to Oral Vaccines in Developing Countries

  2008cites this paper
• Vaccines against enterotoxigenic Escherichia coli

  2008cites this paper
• Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial.

  2008cites this paper
• Construction of non-toxic Escherichia coli and Vibrio cholerae strains expressing high and immunogenic levels of enterotoxigenic E. coli colonization factor I fimbriae.

  2008cites this paper
• Mucosal Immune Responses Against Enterotoxigenic Escherichia coli [ETEC] in Humans

  2008cites this paper
• Needle-free vaccine delivery

  2007cites this paper
• Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico.

  2007cites this paper
• Oral vaccination: where we are?

  2007cites this paper
• Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease.

  2007cites this paper
• Mucosal and Systemic Immune Responses in Patients with Diarrhea Due to CS6-Expressing Enterotoxigenic Escherichia coli

  2007cites this paper
• Feeding Strategies Based on Probing Control for E. coli and V. cholerae Cultivations

  2006cites this paper
• Prevention and Self-Treatment of Traveler's Diarrhea

  2006cites this paper
• Research article

  2004cites this paper